Assessment Of Safety Of UK-390,957
Phase 2
Completed
- Conditions
- Ejaculation
- Registration Number
- NCT00219609
- Lead Sponsor
- Pfizer
- Brief Summary
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1058
Inclusion Criteria
- Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV
Read More
Exclusion Criteria
- No drug related serious adverse events
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Assessment of safety
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇬🇧Devon, United Kingdom